To view the report in PDF format, you first need to download the free Adobe Acrobat Viewer. The Acrobat Viewer will launch the file so that
you can see the document on your monitor and then print it. Download
Adobe Acrobat.
Download the Report
|
|
February 6, 2008
 Psychopharmacologic Drugs Advisory Committee Briefing Document; Zyprexa
Olanzapine Pamoate (OP) Depot
Zyprexa is manufactured by Eli Lilly & Company as a treatment for
schizophrenia and bipolar disorder. According to research presented to
the U.S. Food and Drug Administration (FDA) Psychopharmacological Committee, about one percent of patients
treated with the injectable version experienced excessive sedation as a
side effect within three hours after the injection; two cases were
described as comas. However, all patients recovered fully.
This research was presented to the FDA
Psychopharmacologic Drugs Advisory Committee, which said that the product
appeared to be effective and acceptably safe.
|
OPEN MINDS